Kristin Ashcraft, Co-Founder and CEO of OncoRx Insights, is determined to bring current information to community-based oncologists to help them identify precision therapies for their patients. The AI platform is designed to augment the oncologist's expertise by analyzing molecular diagnostics, pathology reports, and patient history to identify appropriate FDA-approved drugs and possible clinical trials. The aim is to democratize access to advanced treatment information, bringing the capabilities of academic medical centers to the community setting.

Kristin explains, "Our goal is to increase the lifespan of cancer patients by enabling community oncologists to more efficiently identify precision therapies for their patients. We do this through a unique, comprehensive analysis of the molecular diagnostics, patient history, and pathology reports. The reason that we are here is that it can be summed up really well in a study that was recently published in the Journal of Clinical Oncology, in which they found that only 36% of eligible lung cancer patients receive precision medicine therapies. And so OncoRX Insights is focused on bringing greater access to precision medicine for cancer patients."

"Cancer results from genetic mutations from external or inherited causes, and it presents in over a hundred different forms. So as you pointed out, understanding the best possible treatment really is a challenge. But using the molecular diagnostic report and additional information like pathology reports, patient history, understanding those details can really help drive the most targeted treatment to have the best chance of the best outcomes for those patients."

#OncoRxInsights #PrecisionMedicine #CancerCare #AIInHealthcare #Oncology #CommunityOncology #HealthTech #MedTech #CancerTreatment #DigitalHealth #PersonalizedMedicine #HealthcareInnovation #CancerResearch #HealthcareInnovation #RealWorldData

OncoRxInsights.com

Download the transcript here